Biological Treatments

In the past 10 years there has been a dramatic improvement in clinical outcomes for patients with severe psoriasis due to the introduction of a new class of injectable drugs called biologics. These work by targeting specific parts of the immune system which are important in causing the condition.

However, these drugs are very expensive (estimated annual cost is £10,000 per patient) and a significant number of patients fail to respond adequately to treatment with these drugs.

Response to treatment with biologics

As part of its programme of research, PSORT will initially focus on the biologics:

  • adalimumab (a monoclonal antibody that binds specifically to tumour necrosis factor alpha to limit inflammation),
  • ustekinumab (a monoclonal antibody that targets interleukins 12/23; proteins involved with regulating the immune responses) and
  • secukinumab (human monoclonal antibody that binds to and neutralises interleukin‑17A).

The dynamic aspect of PSORT will allow us to include other new biologics and small molecules as they become available to treat psoriasis.

More information on biological treatments is available via NICE.